There's a difference though between allogeneic, one relying on...

There's a difference though between allogeneic, one relying on multiple donors to supply the starting material with an ongoing requirement to re-screen donors and re-establish cell banks for future supply and iPSC's used as a nearly limitless starting material from potentially only one donor for all future treatments

There's a potential time and cost saving down the track.

But regardless of the above, I agree with you that CHM is very undervalued, especially when looking at possible time to commercialisation of our products and with the compelling clinical data achieved to-date. Hence, I have been added regular buyer sub 2c.